Using imaging to assess prostate cancer response to radiation therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the local response of prostate cancer to radiation therapy using advanced imaging techniques. It focuses on men who are either scheduled for radiation treatment or have experienced a recurrence of prostate cancer after previous treatment. The study will utilize multiparametric MRI and standard biopsies to determine the rate of local recurrence in patients, helping to identify those who may benefit from additional local therapies. By understanding the characteristics of local failure, the study seeks to improve treatment options for patients with prostate cancer.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA: men with untreated prostate cancer.

  1. Patients must have histologically or cytologically confirmed prostate cancer. The outside pathology report is acceptable for study entry. Every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, NCI.
  2. Intermediate or high risk prostate cancer (clinical tumor stage T2b or higher, Gleason 7 or higher, or PSA greater than 10). Previously obtained MR imaging may be used for clinical T staging (extracapsular extension, seminal vesicle invasion).
  3. No prior local therapy (prostatectomy, radiation, cryotherapy) or hormonal therapy for prostate cancer.
  4. Age \>18 years.
  5. ECOG performance status \<2 (Karnofsky \>60%).
  6. Radiotherapy is planned as definitive therapy for prostate cancer. For patients not treated at NCI ROB patients must have a radiation oncologist who is willing to collaborate with the ROB and provide documentation of treatment.
  7. Ability of subject to understand and the willingness to sign a written informed consent document.

INCLUSION CRITERIA: for men with presumed prostate cancer relapse

1. Patients must have a history of histologically or cytologically confirmed prostate cancer. The outside pathology report is acceptable for study entry. Every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, NCI
2. Age greater than or equal to 18 years.
3. ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).
4. Radiotherapy (external beam irradiation alone or in combination with hormonal therapy and/or brachytherapy) was delivered as definitive therapy for prostate cancer and documentation is available.
5. Evidence of prostate cancer recurrence (biochemical relapse by the Phoenix definition, enlarging palpable prostatic abnormality, imaging evidence strongly suggestive of local failure)
6. Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

1. Patients unable to tolerate MRI (patients with pacemakers, cerebral aneurysm clips, shrapnel injuries, or other implantable electronic devices or metal not compatible with MRI).
2. Evidence of metastases (pelvic lymph node involvement is not an exclusion criteria). For patients with recurrent prostate cancer, oligometastatic disease (3 or fewer visible metastases) is not an exclusion criterion.
3. Patients with coagulopathies who are at increased risk for bleeding or on active anticoagulation therapy (platelets less than 100,000 per mm\^3 or PT/PTT greater than 1.5 times the upper normal limit (UNL). Patients are eligible if the underlying cause is correctable.
4. Subject s weight exceeding MRI or radiation treatment table tolerance.
5. Patients with active urinary tract infections.
6. Patients with renal insufficiency with a GFR less than 30, due to the fact that they will not be able to undergo gadolinium enhanced MRI.
7. Uncontrolled illness or comorbidity that in the judgment of the PI would preclude participation in the study.
8. Hepatitis B or Hepatitis C active infection.
9. HIV-positive patients are ineligible because HIV is known to increase radiation toxicity and may result in under-dosing or alterations in the treatment plan that would alter the likelihood of local recurrence. Appropriate studies will be undertaken in HIV positive patients when indicated.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Deborah E Citrin, M.D. — National Cancer Institute (NCI)
• Study coordinator: Rukayat O Salau
• Email: rukayat.salau@nih.gov
• Phone: (240) 858-3712

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Shorter Salvage Radiotherapy after Prostate Surgery for Recurrent Prostate Cancer

  This study tests whether a shorter, 4-week salvage radiotherapy schedule is as safe and effective as the standard 5-week schedule for men with prostate cancer that has come back after surgery.

  Recruiting CHU de Quebec-Universite Laval · Gatineau, Quebec and 3 other locations · NCT07483658

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

• New treatment for metastatic prostate cancer using ifinatamab deruxtecan

  This study is testing a new treatment called ifinatamab deruxtecan to see if it helps men with advanced prostate cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 290 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 302 other locations · NCT06925737

• Using a new type of PET scanner for imaging prostate cancer and related conditions

  This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.

  Recruiting Jagiellonian University · Krakow · NCT06242119

• Using 64Cu-SAR-bisPSMA PET to detect prostate cancer spread before surgery

  This study is testing a new imaging method to see if it can help find prostate cancer spread in high-risk patients before they have surgery.

  Recruiting at 34 sites Phase 3 Clarity Pharmaceuticals Ltd · Birmingham, Alabama and 33 other locations · NCT06056830

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.